pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News · Immunology
996
stories
Sep 1, 26
GSK to launch Phase 3 test of mRNA flu vaccine with newer formulation
endpoints
Sep 1, 26
Alumis' TYK2 drug fails in lupus trial; CEO sees 'clear path forward'
endpoints
Sep 1, 26
GSK to launch Phase 3 trial for mRNA-based flu vaccine amid resurgence for the modality
biospace
Sep 1, 26
STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more
stat
Sep 1, 26
Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events
biospace
Sep 1, 26
Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody
fiercebiotech
Sep 1, 26
Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitor
fiercebiotech
Sep 1, 26
GSK catches phase 3 fever after mRNA flu vaccine beats standard shots
fiercebiotech
Sep 1, 26
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
endpoints
Aug 31, 26
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
biopharma dive
Aug 31, 26
UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies
fiercebiotech
Aug 31, 26
FDA OKs Takeda, Protagonist drug for rare blood cancer
biopharma dive
Aug 31, 26
Lilly adds to immune drug pipeline with $2.9B Merida buyout
biopharma dive
Aug 31, 26
Sanofi-backed Electra files for IPO to fund Phase 2/3 immunology drug
endpoints
Aug 31, 26
Lilly to buy TED startup Merida Biosciences in its 13th acquisition of 2026
endpoints
Aug 31, 26
Deal-hungry Lilly strikes up to $2.9B immuno play for Merida
biospace
Aug 31, 26
A winner, a loser, and a mid-stage signal from a major cardiology research conference
stat
Aug 31, 26
Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push
fiercebiotech
Aug 31, 26
Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies
fiercebiotech
Aug 31, 26
BMS’ neuro renaissance was built on back of Celgene mega-merger
biospace
Aug 31, 26
China poses increasing security risk as US biotech innovation edge erodes
biospace
Aug 30, 26
STAT+: FDA approves Protagonist and Takeda’s drug for rare blood cancer
stat
Aug 30, 26
STAT+: Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainua
stat
Aug 29, 26
STAT+: A Novartis drug cut inflammation. Can it improve heart outcomes?
stat
Aug 29, 26
Northwest Naturals Voluntarily Recalls Two Raw Pet Food Products Because of Possible Salmonella & Listeria Monocytogenes Health Risk
fda recalls
Aug 28, 26
Everything Sprouts, LLC Expands Voluntarily Recall to Include Robust Radish Mix Due to Potential E. Coli and Salmonella Risk
fda recalls
Aug 28, 26
BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
biospace
Aug 28, 26
Panorama Produce Recalls Mangoes Due to Possible Salmonella Contamination
fda recalls
Aug 28, 26
STAT+: AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching
stat
Aug 28, 26
BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test
fiercebiotech
← prev
page 18 of 34
next →